Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15320)	2/19/1998 11:34:00 AM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 32384

Henry, >> ...suggest that LAZ3/BCL6 & nuclear hormone receptors repress transcription through shared mechanisms involving SMRT recruitment & histone deacetylation.<< Since LGND is THE transcription company, the ability to repress transcription is highly important to it & that ability leads to more information on how to enhance transcription by interfering with the very factors that repress it. Interestingly, LGND ceased its trials against non-Hodgkins lymphomas in '97, the same year this paper was presented. Hopefully this updated knowledge will permit a more dynamic attack against it. Bernie